Tenapanor for chronic constipation (ACCEL)

Tenapanor has robust prior Phase 3 success in CIC (T3MPO-1/2 trials) with approved mechanism (NHE3 inhibitor, also approved as Ibsrela for IBS-C). Dose-ranging study with 50mg BID likely replicates efficacy. CSBM durable response endpoint is FDA-standard and tenapanor previously hit it. Main risk: dose selection (5mg may fail), but trial succeeds if any arm beats placebo. Strong mechanistic and clinical precedent supports high success probability.

Phase 3 randomized, double-blind, placebo-controlled design and three active doses support a credible efficacy test and improve the chance that at least one dose succeeds. The durable CSBM endpoint is clinically relevant but stringent. Recruiting status, long timeline, and no prior efficacy data provided limit confidence.

Randomized, double-blind, placebo-controlled Phase 3 design and three active doses support a credible efficacy readout. The 12-week durable CSBM responder endpoint is clinically meaningful but stringent, while multiple-dose testing and long treatment introduce multiplicity, tolerability, and execution risk.

Phase 3, randomized, double-blind, placebo-controlled, dose-ranging design and a clinically direct 12-week durable CSBM endpoint support a meaningful chance of success. However, the fields provide no prior efficacy, enrollment, or operational performance data; recruitment and a 451-day timeline add execution and disclosure uncertainty.

Phase 3 double-blind placebo-controlled design with standard durable CSBM endpoint in CIC adults; 26-week treatment and multiple doses (up to 50 mg BID) support efficacy signal detection; recruiting status shows operational start but distant 2027 completion adds execution and data quality risks.

Tenapanor is already FDA-approved for IBS-C (Ibsrela) at 50 mg BID. IBS-C and CIC share identical constipation pathophysiology. A post-hoc analysis of the Phase 3 T3MPO-1 and T3MPO-2 IBS-C trials assessed this exact CIC durable CSBM response endpoint and found highly significant efficacy (p<0.001, 11-15% placebo-adjusted delta). ACCEL is well-powered (N=700) to replicate this.

The trial is still recruiting with no efficacy data yet. Phase 3 in chronic constipation has historically modest success rates, and the primary endpoint (durable CSBM response) is stringent. Multiple dose arms add complexity, and operational risk remains high, suggesting a sub‑50% intrinsic chance of a positive outcome.

Tenapanor is approved for IBS-C (mechanism validated), but Ardelyx's prior Phase 3 CIC trials (T3MPO-1, T3MPO-3) failed the same durable CSBM endpoint. This ACCEL trial is essentially a redesign with three doses (5/25/50mg BID). The durable CSBM bar (≥9/12 wks AND ≥3/4 last wks) is stringent. CIC population differs from IBS-C (less abdominal pain driver), historically tougher. Still recruiting adds execution risk. Prior failures weigh heavily, balanced against known pharmacology and dose-finding flexibility. Modestly below 50%.